FDA, Boehringer Disagree On Non-Inferiority Margin For Micardis Prophylaxis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will tell advisory committee that non-inferiority analysis should account for improvements in standard of care that change effect size.
You may also be interested in...
Panel Accepts FDA's Statistical Take On Micardis, Recommends Limited Use
FDA's Cardiovascular and Renal Drugs Advisory Committee sided with FDA's more conservative statistical analysis of Boehringer Ingelheim's Micardis, rejecting the company's claim that telmisartan demonstrated non-inferiority to ramipril in a pivotal trial
Panel Accepts FDA's Statistical Take On Micardis, Recommends Limited Use
FDA's Cardiovascular and Renal Drugs Advisory Committee sided with FDA's more conservative statistical analysis of Boehringer Ingelheim's Micardis, rejecting the company's claim that telmisartan demonstrated non-inferiority to ramipril in a pivotal trial
Micardis Prophylaxis Should Have Only Limited Patient Population, Cmte. Says
High-risk patients intolerant of ramipril need an alternative to the angiotensin-converting enzyme inhibitor, FDA's cardio-renal advisory committee concludes.